Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 6:48 PM
Ignite Modification Date:
2025-12-24 @ 6:48 PM
NCT ID:
NCT00181857
Eligibility Criteria:
Inclusion Criteria:
Must be a biological child of an ADHD NOS proband. The proband must meet the following criterion:
1. Age: above 18 years
2. Sex: male or female
3. Intelligence quotient (IQ) above 80
4. Met criteria for the diagnosis of attention deficit hyperactivity disorder not otherwise specified (ADHD NOS), by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), as manifested in clinical evaluation and confirmed by structured interview. This is operationalized by either:
* having at least 6 out of 9 current DSM-IV items of either inattention or hyperactivity/impulsivity but \< 5 items from either list in childhood, or
* having 5 out of 9 current DSM-IV items of either inattention or hyperactivity/impulsivity, but not having the 6 current symptoms in either category. This second category will be included independent of the presence or absence of ADHD symptoms in childhood.
5. Had a Clinical Global Impression: ADHD score of 4 (moderately ill) or higher illness severity at a clinical evaluation.
6. Has at least one biological offspring
Exclusion Criteria:
1. No adequate informant is available to answer the survey questions.
2. Sensorimotor deficits. (These include deficits that would impede the survey process, e.g. profound deafness, blindness, inadequate command of the English language, or profound disorders of language.)
3. Psychosis, autism, schizophrenia.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00181857
Study Brief:
Protocol Section:
NCT00181857